Stay updated on Immunotherapy with TILs in Metastatic Cancer Clinical Trial
Sign up to get notified when there's something new on the Immunotherapy with TILs in Metastatic Cancer Clinical Trial page.

Latest updates to the Immunotherapy with TILs in Metastatic Cancer Clinical Trial page
- CheckyesterdayChange DetectedA banner announces an NIH-wide transition from the term “Artificial Intelligence” to “Super Intelligence” and links to transition updates and FAQs.SummaryDifference1%

- Check8 days agoChange DetectedThe footer revision identifier changed from v3.7.1 to v3.7.2 while the study record page continued to display a 403 Forbidden error.SummaryDifference0.2%

- Check15 days agoChange DetectedThe site footer revision marker changed from v3.7.0 to v3.7.1 on the 403 error page.SummaryDifference0.2%

- Check36 days agoChange DetectedThe study page now displays a 403 Forbidden error, replacing the detailed study content with a minimal error screen. Only navigation elements like Home and the site footer remain, blocking access to core trial information.SummaryDifference23%

- Check50 days agoChange DetectedThe study's update log was modified to include two new dates (2026-09-01 and 2026-08-29) and remove two earlier dates (2026-08-28 and 2026-08-27), indicating administrative record-keeping rather than changes to the study itself.SummaryDifference0.1%

- Check57 days agoChange DetectedThe revision log was updated with new entries dated 2026-08-27 and 2026-08-28 and a new Revision: v3.6.6. Older revisions dated 2026-08-18 and 2026-08-19 and Revision: v3.6.5 appear to have been removed.SummaryDifference0.2%

Stay in the know with updates to Immunotherapy with TILs in Metastatic Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Immunotherapy with TILs in Metastatic Cancer Clinical Trial page.